25 min

Clinical Insight: Engaging PWID in HCV Care eViralHepatitis Review

    • Medicine

People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and impede efforts for hepatitis C eradication.

In this issue, Dr. Arthur Kim from Massachusetts General Hospital and Harvard Medical School provides a clinical perspective on identifying and overcoming the barriers that prevent PWID from effectively receiving HCV treatment.

Take our post-test to claim CME credits.

To read a companion newsletter click here.


Hosted on Acast. See acast.com/privacy for more information.

People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and impede efforts for hepatitis C eradication.

In this issue, Dr. Arthur Kim from Massachusetts General Hospital and Harvard Medical School provides a clinical perspective on identifying and overcoming the barriers that prevent PWID from effectively receiving HCV treatment.

Take our post-test to claim CME credits.

To read a companion newsletter click here.


Hosted on Acast. See acast.com/privacy for more information.

25 min